Mild to moderate severity of COVID-19 infection. Andrographolide Andrographis paniculate Favipiravir Coronavirus-2019 SARS-CoV-2
Conditions
Interventions
The intervention arm is Andrographolide (60 mg) 1x3 for 5 days plus Favipiravir (200 mg) 9x2 for 1 day then 4x2 for 4 days.,The control arm is Favipiravir (200 mg) 9x2 for 1 day then 4x2 for 4 days a
Experimental Drug,Active Comparator Drug
Andrographolide and Favipiravir ,Favipiravir alone
Sponsors
Ratchadapisek Somphot Fund, Chulalongkorn University
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: 1. SARS-CoV-2 RT-PCR positive 2. Mild severity of COVID-19 infection 3. Moderate severity of COVID-19 infection
Exclusion criteria
Exclusion criteria: 1. Required High flow nasal cannula (HFNC) support 2. Required NIV FiO2 >0.6 3. Allergu to Andrographolide or Favipiravir 4. AST or ALT > 5ULN at baseline 5. ESRD, cirrhosis, Chronic lung disease, COPD
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Proportion of patients developing Severe pneumonia 6 months Number of patients developing severe pneumonia defined as required High flow nasal cannula (HFNC) support or required NIV | — |
Secondary
| Measure | Time frame |
|---|---|
| Compare proinflammatory cytokine 6 months Laboratory test for proinflammatory cytokine such as CRP, IL-6 at day 7, 14 ,Hepatotoxicity and other adverse events 6 months Laboratory test for liver function test at day 7, 14 | — |
Countries
Thailand
Contacts
Public ContactThaninee Prasoppokakorn
Chulalongkorn University
Outcome results
None listed